This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutTALZENNA MoATalzenna MoAgBRCA testingIdentifying patientsGuidelinesStudy designStudy designBaseline characteristicsEfficacy & SafetyTALZENNA efficacyPrimary endpoint & subgroup analysisSecondary endpoints: ORRSecondary endpoint: OSExploratory endpoints: DoR & TTRTALZENNA safetySafety and tolerabillityAdverse eventsHaematologic/Nonhaematologic AEsPatient-reported outcomes with TALZENNAPatient-reported outcomesGHS/QoLBreast symptomsDosingDosingDose recommendation and special populationsDose modifications/managementPatient ProfilesSupport & ResourcesSupport & ResourcesMaterials
Significantly improved breast symptoms vs chemotherapy1*†​​​​​​​ Estimated overall mean change from baseline in breast symptoms: Prespecified exploratory endpoint‡ Adapted from Litton et al. Ann Oncol. 2020.1​​​​​​​

PROs were included as exploratory endpoints in this open-label study; analyses were prespecified and adjustments for multiplicity were not made. No efficacy conclusions can be made from these data.2​​​​​​​

Significantly delayed time to definitive clinically meaningful deterioration§ in patient-reported breast symptoms vs chemotherapy1ll Time to definitive clinically meaningful deterioration in breast symptoms: Prespecified exploratory endpoint (medians not reached) Adapted from Litton et al. Ann Oncol. 2020.1

PROs were included as exploratory endpoints in this open-label study; analyses were prespecified and adjustments for multiplicity were not made. No efficacy conclusions can be made from these data.2

AE=adverse event; Cl=confidence interval; GHS=global health status; ITT=intent-to-treat; PFS=progression-free survival; PROs=patient-reported outcomes; QoL=quality of life.Conducted in the PRO-evaluable population, defined as those in the ITT population with a baseline assessment and at least 1 post-baseline assessment. Capecitabine, eribulin, gemcitabine, or vinorelbine. Results from longitudinal repeated measures analyses (mixed-effects model). Defined as the time from randomization to the first observation with a ≥10-point increase and no subsequent observations with a <10-point increase from baseline. Results analyzed with the use of a stratified log-rank test, summarized with the use of Kaplan-Meier methods. Explore more Dosing
References:Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535.Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation (supplementary appendix). N Engl J Med. 2018;379(8):753-763.Data on file. Pfizer Inc., New York, NY.TALZENNA Summary of Product Characteristics. 
​​​​​​​▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of full SmPC for how to report adverse reactions.

Legal Category: S1A 
Further information is available upon request

PP-TAL-IRL-0061 April 2023
Patient-reported outcomes with TALZENNA Significantly longer PFS

Superior to chemotherapy in delaying disease progression4

 See the data  Manageable safety profile 

AEs were manageable with a low discontinuation rate4

 Review safety
TALZENNA Summary of Product Characteristics Product CharacteristicsLoading

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.